All Phenotypes Hspd1<tm1c(EUCOMM)Hmgu> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Hspd1^{tm1c(EUCOMM)Hmgu}/Hspd1^{tm1c(EUCOMM)Hmgu} Tg(Tek-cre)12Flv/0	involves: Black Swiss * C3H * C57BL/6 * C57BL/6N	MGI:6385861
cn2	Hspd1^{tm1c(EUCOMM)Hmgu}/Hspd1^{tm1c(EUCOMM)Hmgu} A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺	involves: Black Swiss * C57BL/6 * C57BL/6N * FVB/N	MGI:6385859

Allelic Composition	Hspd1^{tm1c(EUCOMM)Hmgu}/Hspd1^{tm1c(EUCOMM)Hmgu} Tg(Tek-cre)12Flv/0
Genetic Background	involves: Black Swiss * C3H * C57BL/6 * C57BL/6N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hspd1^{tm1c(EUCOMM)Hmgu} mutation (0 available); any Hspd1 mutation (46 available)
Tg(Tek-cre)12Flv mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:282096 )

• embryos are seen at the expected Mendelian ratio at E10.5 but all embryos between E11.5 and E13.5 are dead and absorbed

cardiovascular system

abnormal blood vessel morphology ( J:282096 )

• some vessels exhibit reduced diameters in the head, trunk, and yolk sac at E10.5 but not E9.5

• however, marker analysis shows that endothelial cell differentiation and early development of the yolk sac vascular system appear normal

embryo

embryonic growth retardation ( J:282096 )

• E10.5, but not E9.5, embryos are growth retarded

growth/size/body

embryonic growth retardation ( J:282096 )

• E10.5, but not E9.5, embryos are growth retarded

hematopoietic system

anemia ( J:282096 )

• E10.5 embryos develop severe anemia and are pale

abnormal blood cell morphology ( J:282096 )

• E10.5 embryos exhibit an abnormally low number of blood cells in embryos or yolk sacs

decreased erythrocyte cell number ( J:282096 )

• the numbers of yolk sac erythrocytes are reduced at E9

• however, blood distribution in yolk sacs is similar to controls at E8.5 and the numbers of yolk sac erythrocytes are normal at E8.5

abnormal erythrocyte physiology ( J:282096 )

• cell apoptosis of yolk sac erythrocytes is increased at E9 but not E8.5

• treatment with cyclosporine A decreases erythrocyte cell apoptosis

• mitochondrial membrane potentials of Ter119+ erythrocytes from E8.5 yolk sacs are slightly, but significantly, lower than in controls

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:283049 )

• all mice die within 14 weeks post tamoxifen injection

cardiovascular system

enlarged heart ( J:283049 )

• mice show enlarged hearts 11 weeks post tamoxifen injection

abnormal heart ventricles weight ( J:283049 )

• ratio of ventricular weight to body weight is increased at 11 weeks post tamoxifen injection

thin ventricular wall ( J:283049 )

• ventricular wall thinning is seen at 11 weeks post tamoxifen injection

dilated heart ventricle ( J:283049 )

• ventricular chamber dilation is seen at 11 weeks post tamoxifen injection

cardiac fibrosis ( J:283049 )

• hearts show severe cardiac fibrosis at 11 weeks post tamoxifen injection

abnormal cardiovascular system physiology ( J:283049 )

• increase in number of apoptotic cells is seen in hearts at 11 weeks post tamoxifen injection

dilated cardiomyopathy ( J:283049 )

• mice develop dilated cardiomyopathy after tamoxifen injection

decreased ventricle muscle contractility ( J:283049 )

• left ventricle fractional shortening and ejection fraction are slightly decreased at 9 weeks and further decreased at 11 and 13 weeks after tamoxifen injection

abnormal heart echocardiography feature ( J:283049 )

• left ventricle systolic function represented by fractional shortening and ejection fraction is slightly decreased at 9 weeks post tamoxifen injection and further increased at 11 and 13 weeks after tamoxifen injection

• enlarged left ventricle chamber and ventricular wall thinning are seen at 11 and 13 weeks after tamoxifen injection

• left ventricle systolic function further deteriorates at 11 and 13 weeks after tamoxifen injection

• however, ventricular wall thickness and internal dimension of the heart are not altered at 9 weeks post tamoxifen injection

congestive heart failure ( J:283049 )

• mice develop dilated cardiomyopathy and heart failure after tamoxifen injection

cellular

abnormal mitochondrial physiology ( J:283049 )

• activities of complex I and complex III in mitochondria are impaired at 9 weeks post tamoxifen injection

• activities of all four complexes in mitochondria are impaired at 11 weeks post tamoxifen injection

• cardiomyocytes show reduced mitochondrial potential and increased mitochondrial ROS levels at 9 weeks post tamoxifen injection

oxidative stress ( J:283049 )

• cardiomyocytes show increased mitochondrial ROS levels at 9 weeks post tamoxifen injection

muscle